Rethinking Medication Burden in MASLD: Toward More Targeted Deprescribing
-
By
-
Daniella Lee
-
Alexander Chaitoff
-
November 16, 2026
Clinical Scorecard: Rethinking Medication Burden in MASLD: Toward More Targeted Deprescribing
At a Glance
| Category | Detail |
|---|---|
| Condition | Metabolic dysfunction-associated steatotic liver disease (MASLD), defined here as hepatic steatosis greater than 5% on imaging or biopsy with at least one cardiometabolic risk factor. |
| Key Mechanisms | MASLD commonly coexists with cardiometabolic diseases requiring medication management; the article discusses potential medication-related harms and the challenge of distinguishing appropriate treatment from hazardous prescribing. |
| Target Population | Community-dwelling adults aged 65 years and older, with particular attention to adults aged 75 years and older with MASLD. |
| Care Setting | Community-dwelling older adults represented in a nationally representative NHANES analysis; the article also discusses individualized deprescribing research and shared decision-making. |
Key Highlights
- In NHANES 2017–2020, polypharmacy increased with age and was comparable between participants with and without MASLD across most age categories.
- Among adults aged 75 years and older, polypharmacy prevalence was 60.3% with MASLD versus 42.7% without MASLD (p < 0.01).
- Participants with MASLD had more cardiometabolic conditions, while cardiometabolic medication use was equivalent across most age categories.
- In the oldest age group, MASLD was associated with more antihypertensive and antidiabetic prescriptions; sedating medication use and hyperpolypharmacy did not differ between groups.
- The article states that evidence remains limited on whether reducing medication counts improves clinical outcomes or patient satisfaction.
Guideline-Based Recommendations
Diagnosis
- The study identified MASLD using image-guided assessment of hepatic steatosis alongside exam- or medication-derived evidence of cardiometabolic risk.
Management
- The article says clinicians need to involve patients in shared decision-making about treatment risks and benefits.
- The authors suggest that deprescribing research could focus on people with conditions that may heighten frailty risk or alter medication metabolism, and on high-risk individuals unlikely to benefit from continued medication.
Monitoring & Follow-up
- The authors call for further epidemiologic research assessing clinical outcomes across different levels of medication use in people with MASLD.
- The authors call for research to establish whether structured, individualized deprescribing interventions affect outcomes in this population.
Risks
- The source notes that older adults are susceptible to harms associated with polypharmacy, including mortality.
- Higher medication use may represent appropriate treatment or potentially hazardous prescribing; the study does not resolve which applies to most patients with MASLD.
Patient & Prescribing Data
Community-dwelling adults aged 65 years and older in NHANES 2017–2020; the reported age-specific difference was among participants aged 75 years and older.
Among those aged 75 years and older, polypharmacy prevalence was 60.3% with MASLD and 42.7% without MASLD. In this group, participants with MASLD had more antihypertensive and antidiabetic prescriptions, but sedating medication use and hyperpolypharmacy did not differ.
Clinical Best Practices
- The article says clinicians need to involve patients in shared decision-making about treatment risks and benefits.
- The study does not establish whether higher medication counts indicate undertreatment, overtreatment, or appropriate treatment.
- The authors call for research on individualized deprescribing approaches; evidence remains limited on whether reducing medication counts improves clinical outcomes or patient satisfaction.
Related Resources & Content
Based on findings from:
Beyond the Prescription Count: MASLD, Polypharmacy, and Moving to More Precise Deprescribing
Daniella Lee, Alexander Chaitoff. Journal Of General Internal Medicine, 2026.
https://link.springer.com/article/10.1007/s11606-026-10755-2
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.